このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors

2026年11月12日 更新者:Shanghai Henlius Biotech

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HLX49 (Anti-HER2 Biparatopic and Bispecific ADC) in Participants With Advanced/Metastatic Solid Tumors

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.

調査の概要

詳細な説明

In the phase Ia of this study, an accelerated titration and 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX49 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX49.

In phase Ib of this study, the Safety Review Committee will recommend dose groups for expansion based on the safety, efficacy, and PK data of the dose escalation phase. The dose expansion part will enroll patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have previously failed first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. Patients will be randomized to receive different doses of HLX49 or the active comparator (trastuzumab deruxtecan, T-DXd).

研究の種類

介入

入学 (推定)

222

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Willing and able to provide written informed consent and comply with the study protocol.
  2. Age: 18 to 75 years for Phase Ia; ≥ 18 years for Phase Ib. 3.Tumor Type & Prior Treatment: Phase Ia: Histologically or cytologically confirmed advanced or metastatic solid tumors that are refractory to standard treatment, or for which no standard treatment is available.

Phase Ib (GC/GEJC cohort): Histologically or cytologically confirmed advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) that has progressed during or after exactly one prior line of systemic therapy containing trastuzumab (or a biosimilar).

4.Confirmed HER2-positive status (Phase Ia: IHC 3+ or 2+; Phase Ib: IHC 3+ or IHC 2+/ISH+).

5.ECOG performance status score of 0 or 1. 6.At least one measurable lesion. 7.Life expectancy of more than 3 months. 8.Adequate washout period from prior treatments (e.g., at least 28 days for chemotherapy, radiotherapy, immunotherapy, or major surgery; at least 14 days for targeted therapy or hormone therapy) and recovery of previous treatment-related adverse events.

9.Must provide a tumor tissue sample for biomarker evaluation. 10.Adequate organ and bone marrow function as defined by protocol-specified laboratory tests.

11.Male and female participants with reproductive potential must agree to use highly effective contraception methods; female participants of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. History of other malignant tumors within 2 years prior to the first dose (with exceptions for cured early-stage cancers like cervical carcinoma in situ or non-melanoma skin cancer).
  2. History of severe eye diseases (e.g., severe keratopathy or moderate to severe dry eye).
  3. History of or current interstitial lung disease (ILD) or non-infectious pneumonitis requiring systemic steroids.
  4. Severe allergic reactions to monoclonal antibodies or allergy to any component of the investigational product.
  5. Active systemic infections requiring intravenous antibiotics.
  6. Requirement for treatment with systemic corticosteroids or other immunosuppressive medications within 2 weeks prior to the first dose.
  7. Clinically significant cardiovascular diseases, including but not limited to: severe/unstable angina, myocardial infarction within 6 months, symptomatic congestive heart failure, LVEF <50%, poorly controlled hypertension, or clinically significant prolonged QTc interval.
  8. Symptomatic or uncontrolled brain or meningeal metastases, or spinal cord compression.
  9. Active or suspected autoimmune diseases (exceptions apply for well-controlled type 1 diabetes and autoimmune hypothyroidism on replacement therapy).
  10. Unhealed major wounds or anticipation of major surgery during the study.
  11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  12. Use of strong CYP3A inhibitors or inducers within 2 weeks prior to the first dose.
  13. Active tuberculosis.
  14. Known history of immunodeficiency, including HIV, or history of solid organ transplantation.
  15. Active Hepatitis B (HBV) or Hepatitis C (HCV) infection (exceptions apply for stable/controlled HBV or HCV meeting specific viral load criteria).
  16. Pregnant or breastfeeding females.
  17. Subjects who are assessed as unsuitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Ia (Dose Escalation)

Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

実験的:Ib HLX49 Dose 1 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

実験的:Ib HLX49 Dose 2 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

実験的:Ib HLX49 Dose 3 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

アクティブコンパレータ:Ib Trastuzumab deruxtecan (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first Administration
時間枠:From first dose to the end of Cycle 1 (each cycle is 3 weeks).

DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 3 weeks (21 days) after the first administration of HLX49.

From first dose to the end of Cycle 1 (each cycle is 3 weeks).
The maximum tolerated dose (MTD) of HLX49
時間枠:From first dose to the end of Cycle 1 (each cycle is 3 weeks).

The highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX49.

From first dose to the end of Cycle 1 (each cycle is 3 weeks).
RP2D
時間枠:Approximately up to 24 months.

The recommended phase 2 dose (RP2D) of HLX49 in participants with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma.

Approximately up to 24 months.
Objective response rate (ORR) assessed by IRRC
時間枠:Approximately up to 24 months.

Percentage of participants with complete response (CR) and partial response (PR) based on independent radiographic review committee (IRRC) assessment.

Approximately up to 24 months.

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective response rate (ORR)
時間枠:Approximately up to 24 months.

Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment.

Approximately up to 24 months.
Duration of response (DOR)
時間枠:Approximately up to 24 months.

Length of time response continued based on investigator and IRRC assessment.

Approximately up to 24 months.
Progression-free survival (PFS)
時間枠:Approximately up to 24 months.

The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause, whichever occurred first.

Approximately up to 24 months.
Overall survival (OS)
時間枠:Approximately up to 24 months.

Time from the date of enrollment to the date of death for any cause.

Approximately up to 24 months.
Cmax
時間枠:Up to 21 days after the first dose.

Maximum serum concentration (Cmax) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
Tmax
時間枠:Up to 21 days after the first dose.

Time to maximum serum concentration (Tmax) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
T1/2
時間枠:Up to 21 days after the first dose.

Elimination half-life (t1/2) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
ADA (anti-drug antibody)
時間枠:Approximately up to 24 months.

Positive rate of anti-HLX49 antibodies (ADA).

Approximately up to 24 months.
NAb (neutralizing antibody)
時間枠:Approximately up to 24 months.

Positive rate of neutralizing antibodies (NAb) against HLX49.

Approximately up to 24 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2029年12月1日

研究の完了 (推定)

2030年12月1日

試験登録日

最初に提出

2026年11月12日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • HLX49-FIH101

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する